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Abstract
Amphetamine exposure transiently increases CaMKIIα expression in the nucleus accumbens
(NAcc) shell and this persistently increases local GluA1 S831 phosphorylation and enhances
behavioral responding to the drug. Here we assessed whether transiently interfering with CaMKII
signaling using a dominant-negative CaMKIIα mutant delivered to the NAcc shell with herpes
simplex viral (HSV) vectors could reverse these long-lasting biochemical and behavioral effects
observed following exposure to amphetamine. As expected, transient expression of CaMKIIα
K42M in the NAcc shell produced a corresponding transient increase in CaMKIIα and decrease in
pCaMKIIα (T286) protein levels in this site. Remarkably, this transient inhibition of CaMKII
activity produced a long-lasting reversal of the increased GluA1 S831 phosphorylation levels in
NAcc shell and persistently blocked the enhanced locomotor response to and self-administration
of amphetamine normally observed in rats previously exposed to the drug. Together, these results
indicate that even transient interference with CaMKII signaling may confer long-lasting benefits
in drug sensitized individuals and point to CaMKII and its downstream pathways as attractive
therapeutic targets for the treatment of stimulant addiction.
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INTRODUCTION
Previous exposure to psychostimulants such as amphetamine and cocaine enhances
subsequent neurochemical and behavioral responding to the drug. These phenomena are
thought to contribute to the transition from casual drug use to addiction (Robinson and
Berridge, 1993; Vezina, 2004). A brain area prominently linked to the generation of
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addictive behaviors is the nucleus accumbens (NAcc) shell (Anderson et al., 2008). We
recently showed that amphetamine exposure transiently increases expression of the Ca2+/
calmodulin-dependent protein kinase II (CaMKII) α isoform in this site and that transient
viral overexpression of CaMKIIα mimics the behavioral effects of amphetamine exposure in
rats (Loweth et al., 2010). Conversely, NAcc shell infusion of a CaMKII inhibitor (KN93)
prevents cocaine-induced reinstatement of drug seeking (Anderson et al., 2008) as well as
the expression of enhanced NAcc dopamine (DA) overflow (Pierce and Kalivas, 1997),
cocaine-induced locomotion (Pierce et a., 1998) and amphetamine self-administration
(Loweth et al., 2008) normally observed in sensitized rats. However, KN93 affects not only
CaMKII and other protein kinases, but also L-type Ca2+-channels (Li et al., 1992; Gao et al.,
2006), and an inhibitor of these channels produces the same biochemical (Pierce and
Kalivas, 1997) and behavioral effects (Pierce et al., 1998; Anderson et al., 2008) as KN93.
Furthermore, these studies did not directly assess the possibility that transient NAcc shell
CaMKII inhibition could have long-lasting effects on behavioral responding to
psychostimulants, a possibility suggested by our earlier work showing that transient
increases in CaMKIIα in this region lead to long-lasting neuroadaptations that contribute to
the maintenance of sensitization (Loweth et al., 2010). Thus, in the present study, we used a
CaMKII- and brain-region-specific transient inhibition strategy to determine whether
interfering directly with endogenous CaMKII signaling within the NAcc shell could
persistently reverse long-lasting behavioral manifestations of amphetamine sensitization.
METHODS
Strategy for CaMKII inhibition by viral-mediated expression of a K42M mutant
Replication-deficient herpes simplex virus (HSV) viral vectors were constructed and
packaged as previously described by us (Neve et al., 1997; Loweth et al., 2010). These
vectors were used because they produce transient overexpression of the transgene that peaks
3–4 days post-infection and returns to baseline by day 8 post-infection (Neve et al., 1997;
Carlezon and Neve, 2003; Loweth et al., 2010). In addition, local viral infection permits
functional testing of specific groups of neurons in specific brain areas (here the NAcc shell).
We chose to transiently express a CaMKIIα K42M mutant which is “kinase dead” due to
impaired ATP binding. Such “kinase dead” mutants are commonly used as “dominant-
negative” mutants to interfere with endogenous kinase functions and this has been described
for CaMKII (e.g., Kϋhl et al., 2000; Xiao et al., 2005; Garic et al., 2011). Dominant-
negative effects can be exerted by competition with endogenous kinase for upstream
activators, downstream substrates, or subcellular targeting modules. In the case of CaMKII,
which forms dodecameric holoenzymes, dominant-negative effects can also be exerted by
the formation of heteromeric holoenzymes, which interferes with the intra-holoenzyme
inter-subunit autophosphorylation at T286 that generates Ca2+-independent “autonomous”
CaMKII activity (for reviews, see Coultrap and Bayer, 2012; Lisman et al., 2012). In
addition, the K42M mutant interferes with the targeting of holoenzymes to the NMDA-type
glutamate receptor subunit GluN2 (Bayer et al., 2006; O’Leary et al., 2011), which is
regulated by nucleotide binding to CaMKII (O’Leary et al., 2011) and also generates
“autonomous” activity (Bayer et al., 2001; Bayer et al., 2006). Thus, the K42M mutant of
CaMKII has even greater dominant-negative potential than the “kinase dead” mutants of
most other kinases. The regulation of CaMKII is rather complex (Coultrap and Bayer,
2012), but it should be noted that some cellular functions that simply require Ca2+/
calmodulin-stimulated CaMKII activity may or may not be affected by the presence of
additional “kinase dead” mutant. Thus, the designation as a “dominant negative” mutant (as
done here) is always linked to a specific cellular function; for other functions, a particular
“kinase dead” mutant may or may not act in a dominant negative fashion (for further
discussion, see Wayman et al., 2011).
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Male Sprague-Dawley (locomotion experiments) and Long-Evans rats (self-administration
experiments) weighing 250–275 g on arrival were purchased from Harlan Sprague-Dawley
(Madison, WI) and housed individually with food and water freely available. They were
implanted with chronic bilateral guide cannulae as described previously (Loweth et al.,
2010). For the amphetamine self-administration studies, rats were also implanted with i.v.
catheters as described previously (Suto et al., 2004). All surgical procedures were conducted
using aseptic techniques according to an approved Institutional Animal Care and Use
Committee protocol.
Design and Procedure
Rats in different groups were exposed to repeated intermittent injections of amphetamine or
saline and 2–3 weeks later, infused intracranially into the NAcc shell with HSV-K42M
CaMKIIα or a control infusion (mock) consisting of HSV-LacZ or 10% sucrose vehicle.
Rats in one experiment were tested for their locomotor response to a systemic amphetamine
injection 4 days and again 8 days following infection. Rats in a second experiment were
tested for their self-administration of amphetamine before and after HSV infection. Rats in
additional groups were sacrificed 4 or 8 days following HSV infection to determine the
expression pattern of the transgene and assess its effect on phosphorylation of the AMPA
receptor GluA1 subunit at S831, a CaMKII residue. In these cases, brain sections were
harvested and subsequently assessed using immunoblotting.
Exposure Injections
Exposure injections (5 × 1.5 mg/kg amphetamine or 1.0 ml/kg saline) were administered
every 2–3 days as described previously (Vezina et al., 2002; Suto et al., 2004). S(+)-
amphetamine sulfate was obtained from Sigma-Aldrich and dissolved in sterile saline. Doses
refer to the weight of the salt.
Viral-mediated gene transfer in the NAcc shell
The following HSV vector constructs were used: CaMKIIα K42M and a control vector,
LacZ, which encodes the protein β-galactosidase. LacZ and 10% sucrose vehicle were used
interchangeably for mock-infection control infusions as they have consistently been found to
be without effect (Loweth et al., 2010; Singer et al., 2010). Rats were transported to a
biosafety level 2 facility where, as described previously (Loweth et al., 2010; Singer et al.,
2010) and according to an approved Institutional Biosafety Committee protocol, they were
administered bilateral intracranial microinjections into the NAcc shell of their respective
viral vectors or mock control vehicle. Rats were returned to the colony room 24 hours later.
Locomotor Testing
To assess the effect of transient expression of CaMKIIα K42M in NAcc shell neurons on
sensitized locomotor responding to amphetamine, rats were assigned randomly to different
groups based on exposure (systemic amphetamine or saline) and infection (NAcc shell
HSV-K42M CaMKIIα or mock). Thus, four groups were tested: amphetamine-mock,
amphetamine-K42M, saline-mock, and saline-K42M. 2–3 weeks after the exposure regimen,
rats received their respective NAcc shell microinjections and were tested for their locomotor
response to amphetamine (1.0 mg/kg, i.p.) 4 and 8 days later. On each test day, locomotor
activity was measured 1 hour before and 2 hours after the amphetamine challenge injection
using a bank of 12 activity boxes as described previously (Vezina et al., 2002).
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Self-Administration Training and Testing
To assess the effects of transient expression of CaMKIIα K42M on enhanced amphetamine
self-administration, separate rats were assigned randomly to one of four groups based on
exposure and infection as described above for locomotor testing. 2–3 weeks after the last
exposure injection, rats were trained to self-administer amphetamine on fixed ratio (FR)
schedules of reinforcement and then tested under a progressive ratio (PR) schedule for 4
days pre-infection to visualize enhanced work output and drug intake in amphetamine-
exposed rats (Vezina et al., 2002). The following day, rats were transported to the biosafety
facility and administered their respective NAcc shell microinjections. PR self-administration
testing resumed the next day and continued for 12 days post-infection as described
previously (Loweth et al., 2010). Reinforced lever presses delivered an infusion of
amphetamine (200 µg/kg/infusion) through the i.v. catheter. 6 rats did not satisfy the FR
training criteria and were excluded from the study. The daily PR test sessions were
terminated after 3 hr or after 1 hr elapsed without a drug infusion.
Immunoblotting and Immunohistochemistry
Brains were removed rapidly and flash-frozen on dry ice. Sections (1mm thick) were
obtained with a brain matrix and 2 mm diameter punches taken bilaterally around the
injection cannula tips. Tissue punches were processed, loaded (20µg/lane), run using SDS-
PAGE electrophoresis and developed. The following primary antibodies were used:
CaMKIIα (1:2,000), pCaMKII (T286; 1:1,000), GluA1 (1:1,000), pGluA1(S831;1:500), and
β-Actin (1:2,000) or Tubulin (1:100,000) as a loading control. All antibodies were obtained
from Millipore except for β-Actin (Sigma-Aldrich). Additional rats were used in
immunohistochemistry studies (infection with HSV-LacZ) to visualize the pattern of
infection as described previously (Carlezon and Neve, 2003).
Histology
After the completion of the behavioral experiments, rats were deeply anesthetized and
perfused transcardially with 0.9% saline and 10% formalin and brains were removed and
stained with cresyl violet to identify rats with injection cannula tips located bilaterally in the
NAcc shell. Only rats with both cannula tips in the targeted region were retained for
statistical analyses and their number subsequently indicated as n/group in the appropriate
figure legends. The number of rats that failed to meet this criterion for the locomotor and
self-administration studies was as follows: amphetamine-mock, 7; amphetamine-K42M, 5;
saline-mock, 2; saline-K42M, 3.
Data Analysis
Immunoblot, locomotor and self-administration data were analyzed with 2-way between
ANOVA with Exposure (amphetamine and saline) and Infection (HSV-CaMKIIα K42M
and mock) as the between factors. Post-hoc comparisons were made using the Least
Significant Difference (LSD) test. For locomotion, the data analyzed were the total
locomotor counts obtained following the amphetamine challenge (2-hr) on each test day. For
self-administration, the data analyzed were the total number of infusions obtained on day -1
pre-infection, on day 4 post-infection (when expression of the transgene was maximal), and
averaged over days 8–12 post infection (when the transgene was no longer expressed).
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Transient CaMKII inhibition persistently reverses increased GluA1 S831 phosphorylation
in the NAcc shell of amphetamine exposed rats
Herpes simplex viral (HSV) vectors were used to transiently overexpress an inactive mutant
of CaMKIIα (K42M) in NAcc shell neurons (Fig. 1e) as we have previously described for
active CaMKIIα (Loweth et al., 2010). 2–3 weeks after exposure to amphetamine or saline,
rats received bilateral NAcc shell microinjections of HSV-CaMKIIα K42M or mock-
infection control infusions. CaMKIIα protein and T286-phosphorylation levels were
assessed on day 4 and day 8 post-infection (Fig. 1b–c). Consistent with previous findings
(Loweth et al., 2010), no changes in either CaMKIIα protein or T286-phosphorylation levels
were detected 2–3 weeks after exposure to amphetamine as displayed in the mock-infected
rats. Subsequent infection with HSV-CaMKIIα K42M transiently increased total CaMKIIα
protein levels in both amphetamine and saline treated rats; these returned to baseline levels
by day 8 post-infection (Fig. 1b). In contrast, T286-phosphorylation was transiently
decreased, both in absolute terms (data not shown) and as a ratio of phospho-T286 to total
CaMKIIα (Fig. 1c), confirming that expression of CaMKIIα K42M interfered with
endogenous CaMKII signaling. This effect was also transient and no longer evident by day 8
post-infection (Fig. 1c). The ANOVA conducted on CaMKIIα levels and the ratio of
pCaMKIIα/CaMKIIα showed significant effects of Infection only on day 4 post-infection
(F1,19=20.12, p<0.001 and F1,19=15.90 p<0.001, respectively). No other effects, including
on day 8 post-infection, were statistically significant. Thus, transient viral expression of
CaMKIIα K42M transiently interfered with “autonomy”-inducing CaMKII T286
phosphorylation, which was back to control levels on day 8 post-infection.
As exposure to a sensitizing amphetamine regimen leads to a long-lasting increase in
phosphorylation of GluA1 at S831 in the NAcc shell (Loweth et al., 2010), we then assessed
the effect of transiently inhibiting CaMKII signaling in this site on phosphorylation of this
GluA1 residue. Again, a sustained increase in GluA1 S831 phosphorylation was detected in
the NAcc shell of mock-infected rats 2–3 weeks after exposure to amphetamine. This
increase in phospho-S831 was reversed by CaMKIIα K42M expression on day 4 (Infection,
F1,17=5.70, p<0.05), and, remarkably, remained attenuated on day 8 post-infection
(Exposure, F1,18=10.99, p<0.01) when both CaMKIIα expression and T286 phosphorylation
had returned to baseline levels. No other effects were statistically significant. These findings
were again observed both in absolute terms (data not shown) and as a ratio of phospho-S831
to total GluA1 (Fig. 1d).
Transient CaMKII inhibition in the NAcc shell of amphetamine exposed rats persistently
reverses their enhanced locomotor response to and self-administration of the drug
As expected, rats exposed to amphetamine 2–3 weeks earlier showed a greater locomotor
response to a systemic amphetamine challenge (1.0 mg/kg, i.p.) compared to saline-exposed
controls (Vezina, 2004; Fig. 2). Remarkably, transient CaMKII inhibition in the NAcc shell
persistently reversed this expression of locomotor sensitization by amphetamine. The
enhanced locomotor response was completely abolished in the HSV-CaMKIIα K42M
infected animals, not only on day 4 (Fig. 2a) but also on day 8 post-infection (Fig. 2b), again
a time point when both CaMKIIα expression and T286-phosphorylation had returned to
baseline levels (Fig. 1b–c). Significant effects of Exposure (day 4, F1,21=6.30, p<0.05; day
8, F1,21=4.15, p=0.054) and Infection (day 4, F1,21=9.20, p<0.01; day 8, F1,21=4.43, p<0.05)
were detected on both test days. Thus, we next assessed the effect of transient CaMKII
inhibition on the enhanced amphetamine intake observed following amphetamine exposure
(Vezina, 2004; Vezina et al., 2002). Rats were again randomly assigned to four groups based
on condition of exposure (amphetamine or saline) and infection (bilateral NAcc shell HSV-
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CaMKIIα K42M or mock-infection). As expected (Vezina et al., 2002), rats exposed to
amphetamine and given the opportunity to self-administer the drug i.v. worked significantly
more and as a result obtained more infusions compared to saline-exposed controls (Fig. 3;
day -1 pre-infection, Exposure, F1,28=5.41, p<0.05). However, the day following infection
through to day 4 post-infection when expression of the transgene was maximal,
amphetamine-exposed rats infected with HSV-CaMKIIα K42M no longer displayed
enhanced amphetamine intake, obtaining the same number of infusions as saline-exposed
rats and significantly fewer than mock-infected amphetamine-exposed rats (Fig. 3; day 4
post-infection, Exposure, F1,28=3.58, p=0.07; E × I, F1,28=6.69, p<0.05). Importantly, this
reversal of enhanced amphetamine self-administration was maintained for the full 12 days of
testing post-infection and thus again outlasted the transient interference with CaMKII
signaling achieved by HSV-CaMKIIα K42M (Fig. 3; days 8–12 post-infection, E × I,
F1,25=4.09, p=0.05).
DISCUSSION
Expressing a dominant negative form of CaMKIIα (K42M) that transiently inhibits CaMKII
activity in NAcc shell neurons persistently blocked the expression of two major
manifestations of sensitization by amphetamine. As expected, previously exposing rats to
amphetamine led to sensitized locomotor responding to a challenge injection of the drug
and, in a separate group of rats, enhanced drug intake under a progressive ratio (PR)
schedule of reinforcement (Vezina et al., 2002; Vezina, 2004). Transiently inhibiting
CaMKII activity in the NAcc shell of these rats blocked these manifestations of sensitization
and continued to do so long after expression of the transgene had dissipated, indicating that
continued uninterrupted CaMKII activation is necessary for their maintenance. Previous
studies suggested that CaMKII activity in the NAcc shell is required for the expression of
stimulant sensitization (Pierce and Kalivas, 1997; Pierce et al., 1998; Loweth et al., 2008)
and cocaine-induced reinstatement (Anderson et al., 2008). However, these previous studies
tested the pharmacological inhibitor KN-93 that is known to affect not only CaMKII and
other protein kinases but also to inhibit L-type Ca2+ channels, rendering an interpretation of
results that focuses specifically on CaMKII difficult. The use of HSV mediated delivery of a
CaMKIIα mutant in the present experiments circumvented these shortfalls. Importantly, the
present study is the first to unequivocally demonstrate that transiently inhibiting CaMKII
activity in the NAcc shell can lead to the persistent and selective reversal of enhanced
behavioral responding to amphetamine. Thus, the evidence reported here identifies CaMKII
and the signaling pathways it initiates as attractive therapeutic targets for the treatment of
substance abuse.
CaMKII regulates long-term potentiation (LTP) of synaptic strength, a form of neuronal
plasticity thought to underlie both physiological and addiction-related maladaptive learning
and memory (Loweth et al., 2010; Coultrap and Bayer, 2012). Transient interference with
CaMKII signaling has been shown to persistently reverse LTP when it specifically disrupts
the CaMKII/NMDA-type glutamate receptor complex (Buard et al., 2010; Sanhueza et al.,
2011). CaMKII mediates LTP by increasing both the number and the conductance of
synaptic AMPA-type glutamate receptors (Coultrap and Bayer, 2012), the latter by
phosphorylating their GluA1 subunit at S831 (Derkach et al., 1999; Kristensen et al., 2011).
As normal LTP and LTP-induced GluA1 S831 phosphorylation require NMDA receptor-
bound CaMKII (Barria and Malinow, 2005; Halt et al., 2012) and the CaMKIIα K42M
mutation disrupts this binding (O'Leary et al., 2011), we examined the GluA1 S831
phosphorylation state in our animals. Indeed, previous exposure to amphetamine produced a
sustained increase in GluA1 S831 phosphorylation in the NAcc shell, as reported previously
(Loweth et al., 2010), and it was persistently reversed by transient CaMKIIα K42M
expression in this site. Thus, while the interference with CaMKII signaling was transient, its
Loweth et al. Page 6













effect on at least one important downstream mediator persisted, which may have contributed
to the persistent reduction in the enhanced behavioral output normally observed in
amphetamine sensitized rats. While GluA1 S831A mutant mice do not show impairments in
hippocampal LTP or LTD (Lee et al., 2010), they do show deficits in responding for a
conditioned reinforcer (Crombag et al., 2008). Alternatively, an AMPA receptor
independent effect of CaMKIIα on A-type potassium currents was recently proposed to also
contribute to behavioral sensitization by cocaine (Kourrich et al., 2012).
Notably, CaMKII inhibition affected only the enhanced locomotor response and self-
administration observed in rats previously exposed to amphetamine. HSV-CaMKIIα K42M
and mock-infected rats previously exposed to saline showed the same basal levels of
amphetamine-induced locomotion and amphetamine intake throughout testing. These results
indicate that continued uninterrupted CaMKII signaling in the NAcc shell is necessary
specifically to maintain enhanced drug intake observed in individuals that have been
repeatedly exposed to the drug but not for the initial basal intake seen before drug exposure.
Although further characterization of the molecular mechanisms underlying these effects
awaits further study, the results reported here clearly demonstrate that transient inhibition of
CaMKII provides a viable therapeutic strategy to persistently reverse addiction-related
behaviors.
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Figure 1. HSV-CaMKIIα K42M transiently reduces CaMKIIα T286 autophosphorylation but
persistently reverses the increased phosphorylation of GluA1 at S831 in NAcc shell of
amphetamine exposed rats
Rats received NAcc shell microinjections of HSV-CaMKIIα K42M or mock-infection 2–3
weeks after exposure to amphetamine (AMPH) or saline. Regardless of drug exposure,
HSV-CaMKIIα K42M increased CaMKIIα protein levels (b) but decreased its T286
autophosphorylation, shown here as a ratio to total CaMKIIα (c), on day 4 but not day 8
post-infection. The increased phosphorylation of GluA1 at S831 (shown here as a ratio to
total GluA1) was reversed on day 4 and day 8 post-infection with HSV-CaMKIIα K42M
(d). Representative Western immunoblots are shown in (a). Data are group means+SEM %
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of saline-mock controls (n=4–8/group). **, p<0.01, AMPH exposed mock-infected vs
remaining groups; ***, p<0.001, K42M vs mock; by significant ANOVA followed by LSD
tests. (e) Photomicrograph of β-Galactosidase positive neurons illustrating the site of
infection in NAcc shell (arrow).
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Figure 2. Transient NAcc shell CaMKIIα K42M expression persistently reverses amphetamine-
induced locomotor sensitization
(a–b) Rats were exposed to amphetamine (AMPH) or saline and, 2–3 weeks later, received
NAcc shell microinjections of HSV-CaMKIIα K42M or mock-infection (INF) infusions.
Locomotor responding to AMPH was assessed when protein levels were elevated (day 4)
and once they had dissipated (day 8). Data are shown to the left as group mean (+SEM) 2-
hour total locomotor counts following the AMPH injection 4 (a) and 8 (b) days post-
infection. In each case, time courses of the locomotor responses are illustrated to the right as
group mean (±SEM) locomotor counts obtained before and after the AMPH injection
(arrows). Transient expression of CaMKIIα K42M blocked enhanced AMPH-induced
locomotion at both day 4 and day 8 post-infection. **, p<0.01, ***, p<0.001, AMPH
exposed mock-infected vs remaining groups; by significant ANOVA followed by LSD tests.
n=6–7/group. (c) Location of the injection cannula tips for rats included in the data analyses.
Symbols indicate group affiliation. Line drawings are from Paxinos and Watson, 2005.
Numbers to the right indicate mm from bregma.
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Figure 3. Transient CaMKII inhibition in the NAcc shell of amphetamine exposed rats
persistently reverses enhanced amphetamine self-administration
Rats were exposed to amphetamine (AMPH) or saline and tested under a progressive ratio
schedule of reinforcement 2–3 weeks later. (a) Group mean ± SEM AMPH infusions
obtained on the days before and after NAcc shell HSV-CaMKIIα K42M or mock-infection
(arrow). Cumulative presses required to obtain infusions on the progressive ratio schedule
are also shown. (b) Insets show number of infusions obtained on the day pre-infection (−1),
day 4 post-infection when the transgene was maximally expressed, and averaged over days
8–12 post-infection when the transgene was no longer expressed. AMPH-exposed rats
obtained significantly more infusions on day -1 pre-infection and CaMKIIα K42M
expression blocked this enhanced intake on both day 4 and days 8–12 post-infection. *,
p<0.05, AMPH vs saline exposed; **, p=0.01, AMPH exposed mock-infected vs remaining
groups; by significant ANOVA followed by LSD tests. n=6–9/group. (c) Location of the
injection cannula tips for rats included in the data analyses as described in Fig. 2c.
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